Reviews/COPD Pharmacotherapy/Triple therapy cuts exacerbations
Triple Therapy · COPD-TT-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Two large, blinded, randomised trials found that a single-inhaler triple therapy cut moderate and severe flare-ups compared with two-drug inhalers in people with COPD who had already had flare-ups [1][2]. A concern is that in these trials the comparison group had an inhaled steroid taken away at the start, which could make triple therapy look better than it really is [4][16]. A real-world study that avoided this issue, by only studying people who had never been on an inhaled steroid, found no overall benefit but a clear benefit in those with two or more prior flare-ups [4]. Further observational data point the same way for this high-risk group [5][11], while simpler before-and-after studies without a comparison group are supportive but weak [13][14]. The panel judged the claim strong because trial evidence and the confound-free real-world data agree on exactly the prior-flare-up population the claim describes.
Two double-blind RCTs show triple therapy reduces moderate/severe exacerbations versus dual therapy in patients with prior exacerbations: IMPACT reports a rate ratio of 0.85 versus FF/VI and 0.75 versus UMEC/VI [1], and TRIBUTE a rate ratio of 0.848 (p=0.043) [2]. The ICS-naïve real-world cohort found an overall null hazard ratio of 1.08 (95% CI 1.00-1.16) but 0.83 (95% CI 0.74-0.92) among patients with two or more prior exacerbations [4]. The ETHOS post-hoc shows BGF reducing exacerbation rates versus GFF across eosinophil subgroups in an exacerbation-history population [5], and a controlled cohort found no overall difference but an adjusted readmission HR of 0.14 in those with ≥2 prior exacerbations [11]. Uncontrolled step-up series are directionally consistent, with ≥1-exacerbation rates falling from 100% to 23.1% [13] and an annualised exacerbation rate dropping 11.6% [14]. The contested point: The division is whether triple therapy's advantage is general or confined to the prior-exacerbation subgroup, and how much of the RCT magnitude is real gain versus harm from withdrawing inhaled corticosteroids from the comparator arm [4][16]. The real-world cohort [4] and controlled cohort [11] both show overall null results, so the claim holds only because it is scoped to prior exacerbators.
All 16 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from COPD Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pivotal RCT [1] forcibly withdrew maintenance ICS from the dual (LAMA/LABA) comparator arms at randomisation; part of the apparent triple benefit is comparator harm rather than triple gain, as flagged in [4]. This inflates the RCT effect magnitude.
The benefit is subgroup-restricted, not general: in unselected patients [4] reports an overall null HR 1.08 (1.00-1.16) and [11] finds no overall difference. The claim only holds because it is scoped to prior exacerbators — triple is not superior to dual in the broad COPD population.
Where it remains uncertain. The benefit is subgroup-restricted — overall results are null in real-world cohorts [4][11] — and part of the RCT effect may reflect forced ICS withdrawal from the dual comparator [4][16].
Aleatory
Exacerbation occurrence varies between patients and over time; before/after series [13][14] cannot separate this natural variation and regression-to-the-mean from treatment effect.
The load-bearing papers from a corpus of 16, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large RCT: direct exacerbation reduction vs both dual regimens in exacerbation-history COPD.
“The rate of moderate or severe exacerbations in the triple-therapy group was 0.91 per year, as compared with 1.07 per year in the fluticasone furoate-vilanterol group (rate ratio with triple therapy, 0.85; 95% confidence interval [CI], 0.80 to 0.90; 15% difference; P<0.001) and 1.21 per year in the umeclidinium-vilanterol group (rate ratio with triple therapy, 0.75; 95% CI, 0.70 to 0.81; 25% difference; P<0.001).”
Panel auditInternal validity: high · scope of inference: COPD patients randomized to single-inhaler triple vs dual therapy over 52 weeks; the abstract does not state a prior-exacerbation entry requirement, so the exact claim population is not confirmed in the abstract.Key limitations: abstract does not state prior-exacerbation inclusion criterion · higher pneumonia risk with triple (HR 1.53) · possible ICS-withdrawal effect in comparator arms
Independent RCT (different molecule/sponsor): significant reduction vs dual bronchodilator in ≥1 prior exacerbation.
“Moderate-to-severe exacerbation rates were 0·50 per patient per year (95% CI 0·45-0·57) for BDP/FF/G and 0·59 per patient per year (0·53-0·67) for IND/GLY, giving a rate ratio of 0·848 (0·723-0·995, p=0·043) in favour of BDP/FF/G.”
Panel auditInternal validity: high · scope of inference: Symptomatic COPD with severe/very severe airflow limitation and at least one moderate or severe exacerbation in the previous year, i.e. the prior-exacerbation population.Key limitations: dual comparator is a bronchodilator only, not ICS-containing · p=0.043 is marginal · single triple vs single dual regimen
Confound-free (ICS-naive) real-world confirmation of benefit in the exact prior-exacerbation population.
“Among patients with two or more prior exacerbations the HR was 0.83 (95% CI: 0.74-0.92), while for those with prior asthma diagnosis it was 0.86 (95% CI: 0.70-1.06)”
Panel auditInternal validity: medium · scope of inference: ICS-naive COPD patients in UK primary care; shows benefit confined to those with multiple prior exacerbations, not the overall population.Key limitations: observational, residual confounding · overall effect null or against triple · increased severe pneumonia with triple (HR 1.50)
Real-world dual→triple step-up directionally consistent; uncontrolled, weak support.
“The percentage of patients with ≥1 exacerbation decreased from 100 % at visit 1 to 23.1% at visit 3 (p < 0.001).”
Panel auditInternal validity: low · scope of inference: Symptomatic Greek COPD patients stepped up from dual bronchodilation to extrafine triple therapy over 52 weeks.Key limitations: no concurrent comparator · regression to the mean likely · uncontrolled before/after
4 of 16 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
RCT evidence plus confound-free real-world convergence on the precise prior-exacerbation population carries the claim to the top band, tempered only because the benefit is subgroup-restricted and part of the RCT magnitude reflects comparator ICS withdrawal.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Confound-free randomised comparison. The RCT benefit may be partly comparator harm from ICS withdrawal [1][4][16]; the true randomised magnitude in prior exacerbators is unestablished. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An RCT of triple versus dual therapy in prior-exacerbation COPD that does not force ICS withdrawal from the dual comparator arm.
Open question: How large is the triple-versus-dual exacerbation benefit once comparator ICS withdrawal is removed? Why it is still open: The pivotal RCTs withdrew maintenance ICS from the dual arms [1][4][16], and only one observational cohort [4] isolates a confound-free estimate (HR 0.83).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19